CheckMate 459: Long-term survival outcomes with nivolumab versus sorafenib as first-line treatment in aHCC

Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal adenocarcinoma

Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours plus pembrolizumab

Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for resectable pancreatic ductal adenocarcinoma

Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma

Highlights from ASCO 2020

The potential of KRAS inhibitors for non-small-cell lung cancer

NIVOREN: Nivolumab in a 'real world setting' for metastatic clear-cell renal cell carcinoma

Surgical treatment of cholangiocarcinoma and liver metastases

Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line treatment in advanced hepatocellular carcinoma

Health-related quality of life for patients with metastatic pancreatic cancer: Updates from ESMO 2019